What Does "10mg" on a CJC-1295 / Ipamorelin Blend Vial Actually Mean? Dissecting 5/5 Splits, DAC Chemistry, and Formulation Realities

Across peptide sourcing forums, clinical supply channels, and procurement desks—including recent discussions on r/ScienceBioTechnology and r/BodyHackGuide—one question generates persistent confusion among institutional buyers, clinic directors, resellers, and independent researchers alike: When a dual-peptide vial is labeled "10mg CJC-1295 / Ipamorelin," what are you actually receiving? Does it contain 10mg of each sequence, or a combined 10mg split? And why does the distinction between "With DAC" and "No DAC" fundamentally alter the chemical profile of the vial?

Procurement teams frequently encounter fragmented catalog listings. Some vendors list a "10mg blend" without specifying the constituent ratio, leaving buyers to guess whether they are handling a 5mg/5mg split or an unbalanced mixture. Others label products ambiguously as "CJC-1295" without clarifying whether the compound is modified with the Drug Affinity Complex (DAC) or exists as free Mod GRF (1-29). In extreme cases, secondary retailers package uncommon mixtures—such as CJC-1295 With DAC combined with Ipamorelin—under commercial novelty names, confounding buyers who expect standard physiological secretagogue kinetics.

At LeewayGo, we dismantle ambiguous catalog labeling through analytical stoichiometry, synthesis verification, and complete manufacturing transparency. Below is the chemical reality behind dual-peptide vial metrics, counter-ion considerations, and how to verify exactly what is inside your freeze-dried vials.

1. Decoding the "10mg" Label: The 5/5 Ratio vs. 10/10 Conventions

In professional lyophilization and commercial peptide manufacturing, a dual-active vial stating a total mass metric represents the aggregate mass of both active peptide sequences combined, unless explicitly documented otherwise by individual constituent weights.

                  ┌────────────────────────────────────────────────────────┐
                  │           Total Active Peptide Cake: 10mg              │
                  └───────────────────────────┬────────────────────────────┘
                                              │
                    ┌─────────────────────────┴─────────────────────────┐
                    ▼                                                   ▼
       ┌──────────────────────────┐                        ┌──────────────────────────┐
       │   CJC-1295 (No DAC)      │                        │       Ipamorelin         │
       │    Pure Active: 5mg      │                        │    Pure Active: 5mg      │
       │ (Tetrasubstituted 29-AA) │                        │   (Pentapeptide Chain)   │
       └──────────────────────────┘                        └──────────────────────────┘

• The Standard 5/5 Split (10mg Total): When an analytical-grade laboratory lists a standard 10mg blend vial, it almost universally denotes 5mg of CJC-1295 (Without DAC) co-lyophilized with 5mg of Ipamorelin. In standardized production catalogs—such as the LeewayGo Specified Blend catalog code CP10—this configuration is explicitly designated as CJC-1295 Without DAC 5mg + Ipamorelin 5mg (10mg total per vial, packaged as a 10-vial kit). It does not mean 10mg of CJC-1295 plus 10mg of Ipamorelin (which would constitute a 20mg total active cake).
• The 10/10 Ratio (20mg Aggregate): Formulations designated as "10/10" represent a 20mg total active peptide cake containing 10mg of each individual sequence. Reconstituting a 5/5 vial using volume metrics intended for a 10/10 vial cuts the working concentration by half, skewing in-vitro concentration benchmarks or clinical protocol calculations.
• Why the Ratio Must Appear on the COA: Because co-lyophilized cakes form a single homogeneous solid matrix, visual inspection cannot distinguish between a balanced 1:1 molar ratio, an unequal mass split (e.g., 7mg/3mg), or an underdosed mixture. A compliant Certificate of Analysis (COA) must resolve both peaks independently via High-Performance Liquid Chromatography (HPLC) to confirm that both active fractions meet their individual label claims.

2. "With DAC" vs. "Without DAC": Two Fundamentally Divergent Molecules

A major point of failure in peptide procurement is treating "CJC-1295 With DAC" and "CJC-1295 Without DAC" as interchangeable variants of the same molecule. Chemically and pharmacokinetically, they are entirely distinct entities.

CJC-1295 Without DAC (Mod GRF 1-29):
[Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg]-NH2
(MW: ~3367.9 g/mol | Half-Life: ~15 to 30 minutes | Physiologic Pulsatile Kinetics)

CJC-1295 With DAC:
[Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Maleimidopropionyl)]-NH2
(MW: ~3647.2 g/mol | Half-Life: 5.8 to 8.1 days | Continuous Non-Pulsatile Albumin Binding)

CJC-1295 Without DAC (Modified GRF 1-29)

Without DAC, the sequence is a 29-amino-acid synthetic analog of growth hormone-releasing hormone (GHRH), modified at positions 2, 8, 15, and 27 to resist rapid enzymatic cleavage by dipeptidyl peptidase-4 (DPP-4). Its physiological half-life ranges from 15 to 30 minutes. It induces a sharp, physiological pulse of endogenous growth hormone release that mimics natural circadian secretory episodes without desensitizing pituitary somatotrophs.

CJC-1295 With DAC (Drug Affinity Complex)

CJC-1295 With DAC incorporates a maleimidoproline linker coupled to a reactive chemical moiety that forms a stable, covalent bioconjugate bond with circulating serum albumin (Lys³⁰(MPA)). In randomized controlled human clinical trials conducted by Teichman et al. (2006), long-acting CJC-1295 demonstrated an elimination half-life of 5.8 to 8.1 days, sustaining elevated growth hormone and IGF-I secretion for over two weeks following administration.

Why Dual Blends Almost Exclusively Utilize "Without DAC"

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) developed by Raun et al. (1998) that acts as a highly selective growth hormone secretagogue receptor (GHSR-1a) agonist, exhibiting a short biological half-life of roughly 2 hours.

When researchers combine a GHRH pathway activator with a ghrelin receptor agonist, the objective is dual-receptor pulsatile amplification:

1. CJC-1295 (No DAC) triggers GHRH receptor signaling to stimulate growth hormone vesicle synthesis and release.
2. Ipamorelin simultaneously binds GHSR-1a, suppressing somatostatin (the inhibitor hormone) and enhancing pulse amplitude.

Pairing short-acting Ipamorelin with long-acting CJC-1295 With DAC creates a severe pharmacokinetic mismatch: a multi-day continuous baseline elevation cross-paired with a transient 2-hour pulse receptor agonist. Unless a specific investigative model demands continuous non-pulsatile somatotroph stimulation, standard secretagogue blends pair CJC-1295 Without DAC with Ipamorelin.

3. Formulation Matrix: Decoding Secretagogue Formats

4. Analytical Chromatography: Resolving Co-Lyophilized Dual Cakes

In single-sequence manufacturing, a laboratory injects a single compound through an analytical column, yielding a single primary chromatographic peak. In a co-lyophilized blend, quality verification demands an advanced analytical protocol.

A legitimate synthesis facility cannot issue an analytical report that only evaluates the total protein mass. The analytical workflow must feature:

• Dual-Wavelength HPLC Peak Deconvolution: Because the 29-amino-acid chain of CJC-1295 and the 5-amino-acid sequence of Ipamorelin have differing molar extinction coefficients, the chromatographic assay must utilize a gradient mobile phase (typically water/acetonitrile with 0.1% TFA) that clearly resolves two distinct baseline peaks without co-eluting shoulder impurities.
• Independent Mass Confirmation via LC-MS: Liquid Chromatography-Mass Spectrometry must detect the specific monoisotopic mass ions for both sequences—confirming [M+H]⁺ at 3367.9 g/mol for CJC-1295 Without DAC and 711.9 g/mol for Ipamorelin.
• Precise Counter-Ion Exchange: Both peptides must undergo controlled ion-exchange chromatography prior to freeze-drying. If a supplier utilizes crude, unexchanged TFA peptide salts, the acidity of the co-lyophilized cake accelerates peptide fragmentation in aqueous solution, degrading the 28-day stability curve following bacteriostatic reconstitution.

Sourcing Verified Secretagogue Formulations from LeewayGo

Whether you manage an aesthetic practice, coordinate bulk inventory for a peptide brand, or oversee institutional research, eliminating labeling ambiguity protects your operational consistency. Review our detailed physiological overview at the Growth Hormone Secretagogues Research Hub, or explore structural mechanisms in our CJC-1295 & Ipamorelin Secretagogue Guide.

To secure standardized, laboratory-verified secretagogue sequences for your facility:

• Inspect pure single-sequence specifications on our CJC-1295 Without DAC Product Page and Ipamorelin Product Page (available in 2mg, 5mg, and 10mg vials, 10-vial kits).
• Review batch-specific dual-peak chromatograms directly on the LeewayGo COA Verification Portal.
• For verified dual-active formulations, Request a Quote for CJC-1295 Without DAC 5mg + Ipamorelin 5mg or specify high-volume packaging via Direct Inquiry for CP10 (10mg × 10 Vials Configuration) to access tiered manufacturing pricing, OEM private labeling, and full DDP compliant air-freight fulfillment.

Scientific References

1. Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. DOI: 10.1210/jc.2005-1536
2. Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. DOI: 10.1530/eje.0.1390552